Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Laquinimod Phase IIa Study in Active Crohn's Disease
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Demyelination affects temporal aspects of perception: An optic neuritis study.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Sex-related factors in multiple sclerosis susceptibility and progression.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
Poor sleep in patients with multiple sclerosis.
Prevention and treatment of MS: studying the effects of vitamin D.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Centocor briefing document for Ustekinumab, submitted to FDA
[Plasmapheresis in central nervous system disorders].
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study

Pages